GCG and obesity disorder: Moreover, the percentage of participants in clinical trials who stopped the treatment due to AE was 5–15% with most of the new agents, and this percentage was up to 20–30% with some of GLP-1/glucagon RA in phase 2 trials – so a considerable proportion of people may not be able to tolerate the new obesity pharmacotherapies or may be unable to titrate them to the higher and most effective doses.